Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Comprehensive molecular profiling of lung adenocarcinoma

Nature · 2014 · 5.8K citations · Full text

Medicine, Genetics, Oncology +17

Hepatobiliary Cancers

Al B. Benson, Thomas A. Abrams, Edgar Ben‐Josef et al. · Journal of the National Comprehensive Cancer Network · 2009 · 2.3K citations · Full text

Medicine, Oncology, Pathology +14

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Garrett M. Frampton, Alex Fichtenholtz, Geoff Otto et al. · Nature Biotechnology · 2013 · 2.2K citations · Full text

Medicine, Genetics, Oncology +14

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations

Medicine, Genetics, Oncology +17